Astera Labs, Inc. $ALAB Shares Purchased by PDT Partners LLC

PDT Partners LLC boosted its holdings in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 112.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 53,157 shares of the company's stock after buying an additional 28,121 shares during the period. PDT Partners LLC's holdings in Astera Labs were worth $3,172,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Astera Labs by 2,824.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 154,524 shares of the company's stock worth $20,467,000 after buying an additional 149,240 shares during the last quarter. Aigen Investment Management LP boosted its stake in Astera Labs by 50.9% in the 1st quarter. Aigen Investment Management LP now owns 17,920 shares of the company's stock worth $1,069,000 after buying an additional 6,045 shares during the last quarter. Pacific Point Advisors LLC boosted its stake in Astera Labs by 75.0% in the 1st quarter. Pacific Point Advisors LLC now owns 7,000 shares of the company's stock worth $418,000 after buying an additional 3,000 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in Astera Labs by 73.6% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 15,995 shares of the company's stock worth $954,000 after buying an additional 6,783 shares during the last quarter. Finally, Taylor Frigon Capital Management LLC acquired a new stake in Astera Labs in the 1st quarter worth about $1,887,000. 60.47% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ALAB has been the topic of a number of research analyst reports. Jefferies Financial Group raised their price target on Astera Labs from $95.00 to $130.00 and gave the stock a "buy" rating in a research note on Tuesday, July 22nd. Northland Securities lowered Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 price target on the stock. in a research note on Tuesday, July 22nd. Wall Street Zen raised Astera Labs from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Barclays reaffirmed an "overweight" rating and issued a $155.00 price objective (up from $75.00) on shares of Astera Labs in a research note on Thursday, August 7th. Finally, Evercore ISI lifted their price objective on Astera Labs from $104.00 to $215.00 and gave the company an "outperform" rating in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Astera Labs presently has an average rating of "Moderate Buy" and a consensus price target of $135.75.

Astera Labs Price Performance

NASDAQ ALAB opened at $182.20 on Tuesday. The firm has a market capitalization of $30.29 billion, a P/E ratio of 325.36, a P/E/G ratio of 4.62 and a beta of 1.46. Astera Labs, Inc. has a 1-year low of $36.85 and a 1-year high of $199.47. The business's 50-day simple moving average is $134.36 and its 200-day simple moving average is $96.42.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.11. The business had revenue of $191.93 million for the quarter, compared to analyst estimates of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The company's revenue was up 149.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. On average, equities research analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Insider Buying and Selling at Astera Labs

In related news, COO Sanjay Gajendra sold 91,441 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $183.51, for a total transaction of $16,780,337.91. Following the sale, the chief operating officer directly owned 2,170,877 shares in the company, valued at approximately $398,377,638.27. This trade represents a 4.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jitendra Mohan sold 91,441 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $183.51, for a total value of $16,780,337.91. Following the sale, the chief executive officer owned 2,170,877 shares in the company, valued at approximately $398,377,638.27. The trade was a 4.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,728,116 shares of company stock worth $239,272,181. Insiders own 12.50% of the company's stock.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.